Edgar Filing: Cyclacel Pharmaceuticals, Inc. - Form 4

Cyclacel Pharmaceuticals, Inc. Form 4 March 29, 2006

March 29, 20	06										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION									OMB APPROVAL		
Check this box if no longer subject to Section 16. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							Expires: Estimated a burden hou	irs per			
Form 5 obligation may contin	Form 4 or Form 5 obligations may continue.response0.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19400.										
(Print or Type R	esponses)										
1. Name and Ac Chiao Judy	Symbol	Cyclacel Pharmaceuticals, Inc.				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) 150 JOHN F PARKWAY	I FEarliest Transaction Day/Year) 006				Director 10% Owner X_ Officer (give title Other (specify below) below) V.P., Clin. Dev. & Reg. Aff.						
			Amendment, Date Original Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
(City)		Zip) Tal			•		Person				
1.Title of Security2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date any		2A. Deemed Execution Date, if	Code (D) ear) (Instr. 8) (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	-		
Common Stock, par value \$0.001 per share	03/27/2006		Code V J <u>(1)</u>	Amount 48,168	(A) or (D) A	Price (<u>1</u>)	Transaction(s) (Instr. 3 and 4) 46,168	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Cyclacel Pharmaceuticals, Inc. - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. ofNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date	Amou Unde Secur	le and int of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				
Chiao Judy 150 JOHN F. KENNEDY PARKWAY, SUITE 100 SHORT HILLS, NJ 07078			V.P., Clin. Dev. & Reg. Aff.					
Signaturaa								

Signatures

/s/ Paul McBarron, attorney-in-fact 03/29/2006

**Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

(1) Indicates shares received in the liquidation of Cyclacel Group plc as described in the issuer's Registration Statement on Form S-4 (File No. 333-131225)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.